Details for Patent: 12,502,357

« Back to Dashboard

Which drugs does patent 12,502,357 protect, and when does it expire?

Patent 12,502,357 protects XTANDI and is included in one NDA.

This patent has forty-nine patent family members in twenty-nine countries.

Summary for Patent: 12,502,357

Title:	Formulations of enzalutamide
Abstract:	This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.
Inventor(s):	Douglas Alan Lorenz, Sanjay Konagurthu, Randy J. Wald, Jason A. Everett, Sheila Matz, Yuuki Takaishi, Toshiro Sakai, Ryousuke Irie, Shinsuke Oba, Hiroyasu Toyota, Koji Nishimura, Atsushi Kanbayashi
Assignee:	Astellas Pharma Inc , Medivation Prostate Therapeutics LLC
Application Number:	US18/967,829
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 12,502,357
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 12,502,357

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No	12,502,357					TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No	12,502,357					TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-001	Aug 4, 2020	AB	RX	Yes	No	12,502,357					TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS
Astellas	XTANDI	enzalutamide	TABLET;ORAL	213674-002	Aug 4, 2020	AB	RX	Yes	Yes	12,502,357					TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS

International Family Members for US Patent 12,502,357

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013315619
Australia	2018200316
Brazil	112015005432
Canada	2884795